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In order to investigate the involvement of cGMP-de-
pendent protein kinase (cGK) type II in cGMP-provoked
intestinal Cl2 secretion, cGMP-dependent activation
and phosphorylation of cystic fibrosis transmembrane
conductance regulator (CFTR) Cl2 channels was ana-
lyzed after expression of cGK II or cGK Ib in intact cells.
An intestinal cell line which stably expresses CFTR
(IEC-CF7) but contains no detectable endogenous cGK II
was infected with a recombinant adenoviral vector con-
taining the cGK II coding region (Ad-cGK II) resulting in
co-expression of active cGK II. In these cells, CFTR was
activated by membrane-permeant analogs of cGMP or
by the cGMP-elevating hormone atrial natriuretic pep-
tide as measured by 125I2 efflux assays and whole-cell
patch clamp analysis. In contrast, infection with recom-
binant adenoviruses expressing cGK Ib or luciferase did
not convey cGMP sensitivity to CFTR in IEC-CF7 cells.
Concordant with the activation of CFTR by only cGK II,
infection with Ad-cGK II but not Ad-cGK Ib enabled
cGMP analogs to increase CFTR phosphorylation in in-
tact cells. These and other data provide evidence that
endogenous cGK II is a key mediator of cGMP-provoked
activation of CFTR in cells where both proteins are co-
localized, e.g. intestinal epithelial cells. Furthermore,
they demonstrate that neither the soluble cGK Ib nor
cAMP-dependent protein kinase are able to substitute
for cGK II in this cGMP-regulated function.
In intestinal epithelium a cGMP-signaling pathway can ac-
tivate cystic fibrosis transmembrane conductance regulator
(CFTR)1 Cl2 channels, resulting in the net secretion of salt and
water (1, 2). Guanylin and/or uroguanylin, small peptides de-
rived from larger precursor proteins synthesized by intestinal
epithelial cells, may function as the physiological activator of
the cGMP-mediated signaling route in intestine by activating
guanylyl cyclase C located in the apical membrane of entero-
cytes (2–4). Heat-stable enterotoxins secreted by various path-
ogenic strains of Escherichia coli mimic the action of guanylin
and elicit a severe secretory diarrhea by hyperactivating gua-
nylyl cyclase C (2–4).
Localization studies have suggested a key role for a recently
cloned isotype of cGMP-dependent protein kinase (cGK), des-
ignated type II, as the mediator of the cGMP-provoked intes-
tinal Cl2 secretion (5–7). Type II cGK is expressed predomi-
nantly in epithelial cells of the intestine (5–7), although it was
also detected in kidney (6, 8, 9) and brain (6, 8, 10). In contrast,
type I cGK, consisting of a and b isoforms, and shown to act as
a key regulator of cardiovascular homeostasis (11, 12), is not
expressed in enterocytes (7). Furthermore, purified endogenous
pig cGK II, in contrast to bovine lung cGK I, was shown to
activate CFTR in excised membrane patches (13). However, the
mechanism of the apparent cGK isotype selectivity in activat-
ing CFTR was not clear, since both cGK I and cGK II could
phosphorylate immunoprecipitated CFTR in vitro (13). An ex-
planation for this discrepancy might be that cGK II but not
cGK I selectively phosphorylates CFTR in a native environ-
ment. To examine this possibility we investigated activation
and phosphorylation of CFTR in intact cells expressing either
cGK II or cGK Ib. Endogenous expression of cGK isoforms in
intact cells also permitted use of native enzyme in these exper-
iments such that alterations, particularly of cGK II, that occur
during purification could be avoided. Purification of the mem-
brane-bound cGK II requires the use and subsequent removal
of detergents, a procedure which potentially contributes to
nonspecific (hydrophobic) interactions of this enzyme. Further-
more, purification results in partial proteolytic modification of
cGK II and renders cGK II less sensitive to cGMP (5, 13).
For the analyses of the interactions of CFTR and cGK II or
cGK Ib in intact cells, we established a highly efficient co-
expression system in which rat intestinal IEC-CF7 cells previ-
ously stably transfected with CFTR (14) were infected with
recombinant adenoviral vectors containing the cDNA of cGK II
or cGK Ib. Here we report that co-expression with cGK II but
not with cGK Ib renders CFTR sensitive to activation by cGMP
in intact cells. Furthermore, CFTR is shown to be a selective
substrate for only cGK II-mediated phosphorylation under
physiological conditions, providing a possible explanation for
the present and previously (13) observed isotype-specific acti-
vation of CFTR by cGK II.
EXPERIMENTAL PROCEDURES
Materials—Protein A-Sepharose was from Pierce, 3-isobutyl-1-meth-
ylxanthine (IBMX), and rat atrial natriuretic peptide (ANP) from
Sigma, cGMP analogs from Biolog (Bremen, Germany), and
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[32P]orthophosphate, [g-32P]ATP, 125I2, and the enhanced chemilumi-
nescence (ECL) system from Amersham Corp. Polyclonal cGK II or cGK
I antibodies raised against recombinant cGK II or cGK Ib expressed in
E. coli were prepared as described (7). The polyclonal antibody C449
against CFTR (15) was a gift from A. C. Nairn (Rockefeller University,
New York, NY). The cGK substrate peptide 2A3 (RRKVSKQE) and the
Walsh inhibitor peptide (PKI-(5–24)amide) were synthesized by D.
Palm (University of Wu¨rzburg, Germany).
Construction of Adenovirus Vectors Expressing cGK Ib and cGK
II—For the development of the recombinant virus Ad-cGKII, the coding
sequence of rat cGK II (6) was cloned into the multiple cloning site
between the CMV promoter and the bGH-39 untranslated region of the
adenoviral transfer plasmid pZS2 (16). Upstream of the expression
cassette the plasmid also contains 0.5 kilobase 59 terminal sequence of
wild-type adenovirus type 5. The recombinant plasmid cGKII/pZS2 was
linearized with XbaI and ligated with the long XbaI fragment of the
DNA of RR5, an Ad5 mutant carrying a unique XbaI site and a deletion
of the E1 region ranging from nucleotide position 445–3333 (16). The
ligation product was then transfected into the E1a-transformed human
embryonic kidney cell line 293, and after 10–14 days, recombinant
virus was screened for by polymerase chain reaction, recovered, and
plaque-purified as described previously (16). For the construction of the
recombinant virus Ad-cGK Ib, the expression cassette from pCl (an
expression vector obtained from Promega containing the CMV promoter
and the SV40 poly(A)) was cloned into the multiple cloning site of the
adenoviral transfer plasmid pDE1sp1A (a plasmid containing N-termi-
nal E1-deleted sequences of Ad5, obtained from Microbix Biosystems
lnc., Toronto, Canada) to yield the recombinant plasmid pCMVI. Then
the coding sequence of human cGKIb (17, 18) was cloned into the
expression cassette of pCMVI resulting in the plasmid cGKIb/pCMVI.
Recombinant adenovirus was generated via homologous recombination
between cGKIb/pCMVI and pJM17 (Microbix), a bacterial plasmid con-
taining full-length Ad5 DNA, following cotransfection of both plasmids
into 293 cells (19). The titer of the adenoviral preparations was approx-
imately 1 plaque-forming unit per 500 particles.
Culture and Infection of IEC-CF7 Cells—Rat intestine-derived IEC-6
cells stably expressing CFTR (IEC-CF7) were prepared as described
(14) and cultured in Dulbecco’s modified Eagle’s medium supplemented
with 5% fetal calf serum, 0.1 IU/ml insulin, 0.2 mg/ml G418, 0.1 mg/ml
streptomycin, and 0.04 mg/ml penicillin. Two days after plating, con-
fluent (subconfluent in the case of patch clamp analysis) monolayers of
cells were infected by replacing the medium with fresh medium addi-
tionally containing the adenovirus vectors (usually 5 3 109
particles/ml).
Protein Kinase Assays and Immunoblotting—Two days after infec-
tion cells were washed twice with ice-cold phosphate-buffered saline,
scraped with a rubber policeman in buffer A (150 mM NaCl, 10 mM
NaPO4 pH 7.4, 1 mM EDTA, 100 mg/ml trypsin inhibitor, and 20 mg/ml
leupeptin) and homogenized by brief sonication (three bursts of 3 s,
peak-to-peak amplitude 15–20 mm). Cytosol and membranes were sep-
arated by centrifugation at 150,000 3 g for 60 min at 4 °C in an Airfuge.
Protein kinase activity was determined by incubation of the samples (10
mg of protein) at 30 °C for 4 min in 40 ml of 20 mM Tris-HCl, pH 7.4, 10
mM MgCl2, 5 mM b-mercaptoethanol, 0.1 mM 3-isobutyl-1-methylxan-
thine, 25 mM Na-b-glycerophosphate, 200 nM protein kinase A inhibitor
(PKI), 0.1 mg/ml of a cGK substrate peptide 2A3 (RRKVSKQE; see Ref.
18), 1 mCi of [g-32P]ATP, 300 mM unlabeled ATP and cGMP or cGMP
analogs as described (20). Immunoblotting was performed as described
earlier (21). Immunoreactive proteins were detected after incubation
with cGK II or cGK I antibody (1:3000) by the enhanced chemilumines-
cence method and quantitated by the Molecular Imaging System GS-
363 (Bio-Rad) using standards of purified bovine lung cGK I, recombi-
nant rat intestine cGK II expressed in and purified from Sf9 cells (22),
or rat intestinal brush border membranes containing an established
amount of endogenous cGK II.
125I2 Efflux Studies—Cells which had been infected 2 days earlier
were loaded with tracer for 1.5 h under a humidified 95% air, 5% CO2
atmosphere at 37 °C in a modified Meyler solution (108 mM NaCl, 4.7
mM KCl, 1.3 mm CaCl2, 1 mM MgCl2, 0.8 mM NaH2PO4, 0.4 mM
Na2HPO4, 20 mM NaHCO3, 20 mM HEPES, and 10 mM glucose, pH 7.4)
containing 5 mCi/ml 125I2. After removal of extracellular isotope with
three washes of 3 ml of modified Meyler solution, isotope efflux from the
cells was determined at 37 °C by addition and consecutive replacements
of 1 ml of modified Meyler solution at 1–3-min intervals and was
expressed as fractional efflux per minute as described (23).
Whole-cell Patch Clamp Analysis—Whole-cell Cl2 currents were
measured 1 or 2 days after viral infection using a Biologic RK-300
amplifier essentially as described (24). Signals were filtered at 1 kHz,
digitized (Digidata 1200, Axon Instruments Inc., Foster City, CA), and
analyzed using pClamp 6.0 software (Axon Instruments). Heat-polished
patch pipettes (3–6 MV) filled with an intracellular solution containing
120 mM N-methyl-D-glucamine, 85 mM aspartic acid, 3 mM MgCl2, 1 mM
EGTA, 1 mM MgATP, 5 mM N-Tris-(hydroxymethyl)-methyl-2-amin-
oethanesulfonic acid (TES; pH adjusted to 7.3 with HCl; [Cl2], 43 mM)
were used. The extracellular solution contained 140 mM NaCl, 1.2 mM
MgSO4, 1.2 mM CaCl2, 10 mM glucose, and 10 mM TES (pH 7.3). Cells
were clamped at a holding potential of 0 mV and membrane currents
were measured during depolarizing and hyperpolarizing voltage steps
(150 to 290 mV in 20-mV decrements). All experiments were per-
formed at 32 °C.
Phosphate Labeling and Immunoprecipitation of CFTR—Two days
after infection, confluent cells grown in 6-well plates (Costar; 10 cm2/
well) were incubated at 37 °C for 1 h in 1 ml of modified Meyler solution
without phosphate supplemented with 0.5 mCi of [32P]orthophosphate.
Labeled cells were incubated for an additional 20 min with membrane-
permeable cGMP analogs or forskolin in the same medium. Subse-
quently the medium was removed and the cells were lysed with 300 ml
of 1% SDS containing 100 mg/ml leupeptin and 100 mM phenylmethyl-
sulfonyl fluoride. The lysates were diluted 2-fold with a solution of 50
mM Tris-HCl, pH 7.5, 400 mM NaCl, 10 mM EDTA, 200 mM NaF, 40 mM
sodium pyrophosphate, and 5% Nonidet P-40 and were homogenized by
six passages through a thin needle (0.5 3 16 mm). 32P-Phosphorylated
CFTR was immunoprecipitated with a purified anti-CFTR antibody
C449 as described (15), separated by 6% SDS-polyacrylamide gel elec-
trophoresis, visualized by autoradiography, and quantitated with the
Molecular Imaging System GS-363.
RESULTS AND DISCUSSION
Adenovirus-mediated Transfer of cGK Ib and cGK II—To
study the interaction of CFTR with cGK I or II, we used rat
intestinal IEC-CF7 cells stably transfected with CFTR Cl2
channels (14), which contain no detectable endogenous cGK I or
cGK II by immunoblotting (data not shown), as well as ex-
tremely little soluble and no measurable membrane-associated
FIG. 1. Adenovirus-mediated transfer of cGMP-dependent pro-
tein kinases (cGK) in IEC-CF7 cells. Rat intestinal IEC-CF7 cells
stably transfected with CFTR Cl2 channels were infected with 5 3 109
particles/ml (approximately 107 plaque-forming units/ml) of a replica-
tion-deficient adenovirus containing the cDNA of luciferase (mock; solid
bar), cGK II (hatched bar), or cGK Ib (open bar). Two days after
infection, cells were harvested, homogenized, and separated into cytosol
and membrane fractions. Phosphotransferase activity was determined
with a cGK-selective substrate (2A3) in the presence or absence of 10 mM
cGMP and was expressed per milligram of homogenate protein after
correction for basal activity in the absence of cGMP. Inset, immunoblots
of the homogenate (5 mg protein; hom), cytosol (cyt), and membrane
(mem) fractions of cells infected with adenovirus containing cGK Ib
(top) or cGK II (bottom). The blots were labeled with the respective
specific antibodies against cGK I and II. In the lanes at right, 10 ng of
pure cGK I (top) or rat intestinal brush borders containing 10 ng of cGK
II (bottom) were loaded as standards (st). Shown are results of a typical
experiment which was performed three times.
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cGMP-stimulated phosphotransferase activity (Fig. 1). Infec-
tion of IEC-CF7 cells with 5 3 109 particles of replication
deficient adenovirus containing the cDNA of rat cGK II (Ad-
cGK II) resulted in the expression of 0.5 6 0.2 mg of cGK II/mg
protein as assessed by immunoblotting (n 5 4; Fig. 1), which is
in the range of the endogenous cGK II content of isolated rat
enterocytes determined by immunoblotting (0.2–0.4 mg/mg
protein; data not shown). Furthermore, only the full-length
86-kDa form of cGK II was observed in homogenates of Ad-cGK
II-infected IEC-CF7 cells (Fig. 1), which is similar to cGK II in
native rat intestinal brush border membranes (Fig. 1) (7). In
contrast, a mixture of cGK II forms (86 kDa intact and 70 and
75 kDa proteolyzed forms) was present in the purified prepa-
rations of pig cGK II used in previous experiments demonstrat-
ing cGK II-mediated activation of CFTR in excised membrane
patches (5, 12). Infection of IEC-CF7 cells with a similar dose of
adenovirus vector containing the coding region of human cGK
Ib (Ad-cGK Ib) produced a relatively high expression level of
cGK Ib (2.4 6 1 mg/mg protein; detected by immunoblotting,
n 5 4) corresponding to a large increase in phosphotransferase
activity exceeding the activity measured for cGK II by 5-fold
(Fig. 1). In contrast to cGK II, which was associated primarily
with the membrane fraction, cGK Ib was cytosolic (Fig. 1). The
observed subcellular localization of the recombinant cGKs after
adenovirus-mediated transfer are in agreement with the mem-
brane localization of endogenous cGK II (5, 7) and the soluble
character of endogenous cGK Ib (25). The selectivities of the
recombinant cGK II and cGK Ib expressed in the IEC-CF7 cells
for membrane permeant cGMP analogs were similar to those
previously determined for endogenous or recombinant forms of
cGK II and Ib (18, 22, 26, 27),)2 i.e. cGK II was preferentially
activated by 8-pCPT-cGMP over 8-Br-PET-cGMP (Ka 5 0.1 and
1.7 mM, respectively; data not shown), and cGK Ib was more
readily activated by 8-Br-PET-cGMP than by 8-pCPT-cGMP
(Ka 5 0.04 and 0.9 mM, respectively; data not shown). Taken
together, these results show that both the amount and subcel-
lular distribution of cGK isotype expression produced by ade-
novirus-mediated gene transfer in IEC-CF7 cells reflects that
of endogenous cGK I and cGK II, allowing a meaningful com-
parison of the effects of recombinant cGK isotypes on CFTR in
IEC-CF7 cells.
Activation of CFTR by cGMP in cGK II-expressing Cells—
125I2 efflux measurements provide a simple assay for monitor-
ing the activation of CFTR Cl2 channels (14, 23). The cAMP-
elevating agent forskolin caused a large increase in 125I2 efflux
from IEC-CF7 cells (Fig. 2) but not from CFTR-deficient wild-
type or mock-transfected IEC-6 cells (14). In contrast, both the
membrane-permeable cGMP analog 8-pCPT-cGMP and the
cGMP-elevating hormone atrial natriuretic peptide (ANP) (28)
were unable to mimic the forskolin-provoked increase in 125I2
efflux in either IEC-CF7 cells infected with control adenovirus
containing luciferase cDNA (Fig. 2B, mock), or in noninfected
IEC-CF7 cells (data not shown). These results indicate that
cGMP was unable to provoke activation of CFTR via endoge-
nous cAMP-dependent protein kinase (cAK) in cGK-deficient
IEC-CF7 cells under the conditions tested. However, after in-
fection of IEC-CF7 cells with 5 3 109 particles/ml Ad-cGK II,
addition of 8-pCPT-cGMP caused a gradual increase in the
125I2 efflux rate, reaching a maximum after 4 min (14 6 4%/
min above basal, n 5 6; Fig. 2). A 5-fold lower dose of Ad-cGK
II (109 particles/ml) resulted in an approximately 5-fold lower
expression of cGK II, and a 3–4-fold lower increment in 125I2
efflux rate (3.8 6 1.3%/min; n 5 3) in response to 8-pCPT-
cGMP (data not shown). Relatively high doses of Ad-cGK II
(.2 3 1010 particles/ml) were more effective than the standard
dose of 5 3 109 particles/ml in facilitating the 8-pCPT-cGMP-
provoked increase in 125I2 efflux but were also toxic for the
IEC-CF7 cells as judged from their morphology and an in-
creased rate of basal 125I2 efflux (data not shown).
8-pCPT-cGMP was unable to stimulate 125I2 efflux in CFTR-
deficient IEC-6 cells infected with Ad-cGK II (data not shown),
further strengthening the concept that the CFTR Cl2 channel
is the mediator of cGMP/cGK II-enhanced 125I2 efflux in IEC-
CF7 cells. Accordingly, whole-cell patch clamp analysis of Ad-
cGK II-infected IEC-CF7 cells stimulated with 8-pCPT-cGMP
revealed rapid induction of a linear Cl2 current that was in-2 A. B. Vaandrager, unpublished observations.
FIG. 2. cGMP increases iodide efflux in IEC-CF7 cells expressing cGK II but not cGK Ib. Rat intestinal IEC-CF7 cells stably transfected
with CFTR Cl2 channels were infected with replication deficient adenovirus (Ad) containing the cDNA of either luciferase (mock), cGK II, or cGK
Ib. Two days after infection, CFTR activity was monitored by measurements of fractional 125I2 efflux. A, time course of 125I2 efflux in Ad-cGK
II-infected IEC-CF7 cells. At 5 min (arrow) 50 mM 8-pCPT-cGMP (), 0.1 mM ANP (l), 10 mM forskolin (f), or vehicle (control; l) was added to the
efflux medium. B, maximal increment in 125I2 efflux as determined 2 min after addition of forskolin (fors; open bars) and ANP (hatched bars) or
4 min after addition of cGMP analogs (cGMP; solid bars) to IEC-CF7 cells infected as shown. 125I2 efflux was corrected for basal efflux at the same
time points determined in the absence of the agonists. Concentration of the agonists added was as in A, except that 20 mM 8-Br-PET-cGMP was
used to activate cGK Ib. Data are means 6 S.E. of 3–6 experiments.
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distinguishable from forskolin-provoked currents (Fig. 3) (24).
This 8-pCPT-cGMP-triggered anion current was observed in 8
of 9 IEC-CF7 cells infected with Ad-cGK II. In contrast, only in
1 of 6 mock-infected cells was a small increase observed, indi-
cating that cGK II expression was a prerequisite for CFTR Cl2
channel activation.
In excised membrane patches, the activation of CFTR Cl2
channels by purified pig cGK II was relatively slow in compar-
ison to their activation by cAK (13). In Ad-cGK II-infected
IEC-CF7 cells 8-pCPT-cGMP caused a similar sluggish activa-
tion of CFTR (Fig. 2A). As ANP was shown previously to induce
a prompt rise in intracellular cGMP in IEC cells by activating
endogenous guanylyl cyclases (28), the time course of ANP
activation of 125I2 efflux was compared with the response to the
cGMP analog. As shown in Fig. 2A, the rate of ANP-stimulated
125I2 efflux was similar to that observed with the cAMP-ele-
vating agonist forskolin, suggesting that cGK II and cAK are
able to activate CFTR in intact cells with similar kinetics and
that the lag phase in activation by 8-pCPT-cGMP is due to a
relatively slow permeation of the analog across the IEC-CF7
cell membrane. These results also imply that the delayed CFTR
channel opening in response to purified cGK II observed in
excised patches (13) is apparently an in vitro artifact and may
represent the lag time needed for re-anchoring of the solubi-
lized enzyme to the membrane.
In agreement with our previous in vitro observations in
excised membrane patches (13), cGMP activation of CFTR in
intact IEC-CF7 cells was specifically mediated by type II cGK,
since neither 8-Br-PET-cGMP nor ANP provoked an increase
in 125I2 efflux in Ad-cGK Ib-infected cells (Fig. 2B). However,
these cells showed a normal forskolin response, excluding any
deleterious effect of cGK Ib expression on CFTR activation
(Fig. 2B). Furthermore, the ANP-provoked increase in cGMP
did not differ between Ad-cGK II and Ad-cGK Ib-infected IEC-
CF7 cells (data not shown). Since infection of IEC-CF7 cells
with equivalent doses of adenovirus caused a 5-fold higher
expression of cGK Ib than cGK II, and this dose of Ad-cGK Ib
did not stimulate 125I2 efflux, whereas even a 5-fold lower dose
of Ad-cGK II still did, we conclude that cGK II is at least 25-fold
more effective than cGK Ib in activating CFTR Cl2 channels.
However, since both cGK II and cGK I were found to phospho-
rylate immunopurified CFTR and a cloned regulatory domain
fragment of CFTR (CF-2) in vitro with similar kinetics (13), we
next investigated the in situ phosphorylation of CFTR in cGK
II and cGK Ib-expressing IEC-CF7 cells.
Phosphorylation of CFTR in IEC-CF7 Cells—As shown in
Fig. 4, 8-pCPT-cGMP caused an almost 3-fold increase in 32P
labeling of CFTR in Ad-cGK II-infected IEC-CF7 cells. In con-
trast, 8-Br-PET-cGMP had no effect on CFTR phosphorylation
in Ad-cGK Ib-infected cells, despite the fact that CFTR phos-
phorylation in response to forskolin was similar in both cGK Ib
and cGK II-expressing cells. Therefore, the increase in CFTR
phosphoryl content paralleled the activation of CFTR-mediated
125I2 efflux observed upon cGMP application. This suggests
FIG. 3. cGMP increases whole-cell
chloride current in IEC-CF7 cells ex-
pressing cGK II. Rat intestinal IEC-CF7
cells stably transfected with CFTR Cl2
channels were infected with replication-
deficient adenovirus containing the cDNA
of either cGK II or luciferase (mock). One
or two days after infection, whole-cell Cl2
currents were measured. Cells were
clamped at a holding potential of 0 mV,
and membrane currents were recorded
during depolarizing and hyperpolarizing
voltage steps (150 to 290 mV in 20-mV
decrements; see inset above first trace). A,
current traces from cGK II or mock-in-
fected single cells stimulated with
8-pCPT-cGMP (50 mM) and subsequently
forskolin (10 mM). Control traces repre-
sent basal currents prior to stimulation.
B, current-to-voltage relationship of basal
(E) membrane current and the currents
provoked by 8-pCPT-cGMP (l) and fors-
kolin (f) in the cGK II-infected cell shown
in A.
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that selective phosphorylation of CFTR, rather than subtle
differences in the phosphorylation of individual sites within the
CFTRmolecule, may be the molecular basis for the present and
previously (13) observed cGK II isotype-selective activation of
CFTR. The cGK I-mediated phosphorylation of immunoprecipi-
tated CFTR (13) may be another example of promiscuous sub-
strate utilization inherent in in vitro phosphorylation studies.
We might speculate that the different capabilities of the two
cGK isotypes for CFTR phosphorylation in intact cells may be
due to: (i) a potential difference in the structure of the regula-
tory domain of native CFTR in comparison to that of immuno-
precipitated CFTR or (ii) a kinetic advantage of cGK II in
phosphorylating native CFTR due to their co-localization in the
same subcellular (membrane) compartment (20). Even a small
kinetic advantage in phosphorylation may be important for
tipping the balance between phosphorylation and dephospho-
rylation of CFTR in a native environment that may contain
other regulatory components like phosphatases, which are ab-
sent in isolated preparations of CFTR or CF-2. Finally, since
the in vivo phosphorylation data strictly do not distinguish
whether CFTR is directly phosphorylated by cGK II or by
another kinase, the remote possibility that the cGK II isotype-
specific activation of CFTR is at the level of a regulator/cofactor
endogenously expressed in IEC-CF7 cells cannot as yet be ruled
out.
In conclusion, our demonstration that cGK II expression
rendered CFTR sensitive to modulation by cGMP in cells which
did not previously display a cGMP-inducible Cl2 conductance
indicates that cGK II is a key mediator of cGMP-provoked
activation of CFTR in, e.g., intestinal epithelial cells where
both proteins are co-localized (7). This conclusion is also cor-
roborated by the previously observed correlation between the
presence of cGK II and detection of cGMP-induced CFTR-me-
diated Cl2 secretion in different intestinal segments (7). Fur-
thermore, the role of cGK II in mediating cGMP-provoked
activation of CFTR activation cannot be mimicked by cGK I or
cAK in our cell system. In particular, the ascribed role of cAK
in the cGMP-induced activation of CFTR in several cell lines
(29–33) may therefore not be widely valid but restricted to cells
either expressing a type III cGMP-inhibited phosphodiesterase
to elevate cAMP (29) or cells in which very high levels of cGMP
can be attained to cross-activate cAK (30–32). The intestinal
cell lines T84 and Caco-2 used to demonstrate the latter mech-
anism appear nevertheless to be unsuitable models for study-
ing physiological mechanisms, since they do not contain detect-
able levels of cGK II or cGK I (7). Furthermore, we have shown
(7) that the major localization of cGK I in smooth muscle cells
of the villus lamina propria, in contrast to the epithelial brush
border where cGK II is located, makes cGK I an unlikely
endogenous mediator of cGMP effects on CFTR. The particu-
larly intriguing aspect of our present results is the observation
that even when present cGK I cannot substitute for cGK II in
phosphorylating CFTR in intact cells or in stimulating CFTR-
mediated Cl2 conductance. This not only reinforces the caveat
regarding in vitro phosphorylation studies but, more impor-
tantly, may be a clue to mechanisms of subcellular compart-
mentalization of functions.
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